Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 17/20 | 0.55 |
| ▸ | RAF1 | P04049 | 5/20 | 0.51 |
| ▸ | ARAF | P10398 | 4/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | LYN | P07948 | 1/20 | 0.44 |
| ▸ | HCK | P08631 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14219013 | 0.93 | BRAF (0.52) | BRAFRAF1ARAFKDRINSR | |
| SCHEMBL3594600 | 0.88 | BRAF (0.60) | BRAFRAF1ARAFKDRMAPK14 | |
| SCHEMBL3580497 | 0.86 | BRAF (0.60) | BRAFRAF1ARAFKDRMAPK14 | |
| SCHEMBL3583251 | 0.83 | BRAF (0.55) | BRAFRAF1ARAFKDRMAPK14 | |
| SCHEMBL9970921 | 0.81 | BRAF (0.51) | BRAFRAF1ARAFKDRINSR | |
| SCHEMBL3580748 | 0.81 | BRAF (0.51) | BRAFRAF1ARAFKDRMAPK14 | |
| SCHEMBL3592095 | 0.81 | BRAF (0.57) | BRAFRAF1ARAFKDRMAPK14 | |
| SCHEMBL3589071 | 0.80 | BRAF (0.64) | BRAFRAF1ARAF | |
| SCHEMBL3596820 | 0.79 | BRAF (0.49) | BRAFRAF1ARAFKDRLCK | |
| SCHEMBL3584690 | 0.79 | LCK (0.64) | BRAFKDRINSRLCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | claimed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | claimed |
| EP-2057146-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-05-13 | — | — | EP | claimed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | claimed |
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | disclosed |
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | disclosed |
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | disclosed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | disclosed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | disclosed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | disclosed |
| EP-2059508-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2009-05-20 | — | — | EP | disclosed |
| EP-2057146-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008020124-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | FYN, ABL2, LCK | BRAF 11/4885RAF1 10/4885ARAF 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.